title: Chromic phosphate therapy in carcinoma of the ovary.
abstract: BACKGROUND
  Adjuvant therapy with intraperitoneal (IP) chromic phosphate (P-32) instillation in both early and advanced carcinoma of the ovary requires adequate intra-abdominal distribution for maximum therapeutic benefit. Abdominal-pelvic computed tomographic (CT) scanning with water-soluble IP contrast to establish the absence of intra-abdominal adhesions prior to P-32 instillation has not been previously reported.
  
  
  METHODS
  Sixteen patients with carcinoma of the ovary who were offered IP P-32 therapy between January 1988 and December 1992 were retrospectively reviewed. Computed tomographic scans on 13 patients were reevaluated using a modification of Muggia and associates' distribution scoring system.
  
  
  RESULTS
  Of the 16 patients, one had a negative second look operation for stage IIIc carcinoma of the ovary. The remaining 15 with stage I and II disease underwent at least a staging laparotomy, bilateral salpingo-oophorectomy, and omentectomy. The mean time from operation to IP P-32 attempt was 28 days with a range of 17 to 90 days. Adequate distribution was considered present in two of the three cases evaluated by technetium scanning and in four of the 13 cases studied by CT scanning. On review, 12 of 13 cases studied by CT scans revealed some areas of IP contrast exclusion and loculation.
  
  
  CONCLUSIONS
  We suspect that uneven postoperative IP P-32 distribution is common and may be missed by two-dimensional imaging techniques such as technetium scanning or fluoroscopy.
authors.affiliation: Department of Obstetrics and Gynecology, Tufts University School of Medicine, New England Medical Center, Boston, MA.
authors.forename: A
authors.initials: A
authors.lastname: Goodman
authors.forename: L
authors.initials: L
authors.lastname: Bornstein
authors.forename: H
authors.initials: H
authors.lastname: Ball
authors.forename: D M
authors.initials: DM
authors.lastname: Smith
authors.forename: M
authors.initials: M
authors.lastname: Bankoff
mesh_terms: D000328:Adult; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000601:surgery; D017608:Chromium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000601:surgery; D010710:Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D017608:Chromium Compounds; D010710:Phosphates; C509369:chromic phosphate